<DOC>
	<DOCNO>NCT00350038</DOCNO>
	<brief_summary>The rationale study clarify whether supplementation irbesartan ciprofibrate could increase antihypertensive effect , could improve endothelial function , and/or could affect atherogenic small-dense LDL- , oxydized LDL concentration , onto paraoxinase activity CRP insulin level .</brief_summary>
	<brief_title>Irbesartan , Ciprofibrate Their Combination Onto Endothelial Functions</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Ciprofibrate</mesh_term>
	<criteria>hypertensive + dyslipidemic + damage endothelial function hepatic kidney damage , IDDM ( Insulin Dependent Diabetes Mellitus ) Freckson V type hyperlipoproteinaemia The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>